Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome

Cerebrovascular Diseases

Volumn 27, Issue SUPPL. 1, 2009, Pages 126-133

  Fuentes, Blanca ^a   Martínez Sánchez, Patricia ^a   Díez Tejedor, Exuperio ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Coronary arterial disease; Dyslipidemia; Statins; Stroke risk

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NITRIC OXIDE; PLACEBO; PRAVASTATIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOAVAILABILITY; BRAIN HEMORRHAGE; BRAIN PROTECTION; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOMODULATION; INCIDENCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREMEDICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVASCULARIZATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL;

BRAIN ISCHEMIA; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 64149114758     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000200450     Document Type: Conference Paper

References (72)

1. Fuentes B, Ortega-Casarrubios MA, Martinez P, Diez-Tejedor E: Action on vascular risk factors: importance of blood pressure and lipid lowering in stroke secondary prevention. Cerebrovasc Dis 2007;24(suppl 1):96-106.
2. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-1653.
3. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J: Statins and stroke prevention. Cerebrovasc Dis 2007;24:170-182.
4. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904-910.
5. Konishi M, Iso H, Komachi Y, Iida M, Shimamoto T, Jacobs DR Jr, et al: Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke 1993;7:954-964.
6. Prospective Studies Collaboration, Lewing-ton S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deat hs. Lancet 2007;370:1829-1839.
7. Amarenco P, Steg PG: The paradox of cholesterol and stroke. Lancet 2007;370:1803-1804.
8. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G: Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 2006;333:22.
9. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM: Lipid levels and the risk of ischemic stroke in women. Neurology 2007;68:556-562.
10. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM: Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868-1875.
11. Laloux P, Galanti L, Jamart J: Lipids in ischemic stroke subtypes. Acta Neurol Belg 2004;104:13-19.
12. Amarenco P, Labreuche J, Elbaz A, Touboul PJ, Driss F, Jaillard A, et al: Blood lipids in brain infarction subtypes. Cerebrovasc Dis 2006;22:101-108.
13. Amarenco P, Labreuche J, Touboul PJ: High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008;196:489-496.
14. Bang OY, Saver JL, Liebeskind DS, Pineda S, Ovbiagele B: Association of serum lipid indices with large artery atherosclerotic stroke. Neurolog y 2008;70:841-847.
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
16. Heart Protection Study Collaborat ive Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335: 1001-1009.
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357.
19. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al: Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-689.
20. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-228.
21. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
22. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
23. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
24. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG: Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-950.
25. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313-321.
26. Bucher HC, Griffith LE, Guyatt GH: Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128:89-95.
27. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, et al: Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-1802.
28. Di Mascio R, Marchioli R, Tognoni G: Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis 2000;10:85-92.
29. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, et al: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103:387-392.
30. A m a re nc o P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004;35:2902-2909.
31. O'Regan C, Wu P, Arora P, Perri D, Mills EJ: Statin therapy in stroke prevention: a metaanalysis involving 121,000 patients. Am J Med 2008;121:24-33.
32. Crouse JR 3rd, Byington RP, Furberg CD: HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998;138:11-24.
33. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP: Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999;30:2535-2540.
34. Okumura K, Iseki K, Wakugami K, Kimura Y, Muratani H, Ikemiya Y, et al: Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J 1999;63:53-58.
35. Cui R, Iso H, Toyoshima H, Date C, Yama-moto A, Kikuchi S, et al: Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis 2007;194:415-420.
36. Denti L, Cecchetti A, Annoni V, Merli MF, Ablondi F, Valenti G: The role of lipid profile in determining the risk of ischemic stroke in the elderly: a case-control study. Arch Gerontol Geriatr 2003;37:51-62.
37. Schulz UG, Rothwell PM: Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of popu lation-based studies. Stroke 2003;34:2050-2059.
38. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cere-brovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
39. Coull BM: Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined? Stroke 2004;35:2233-2234.
40. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
41. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, et al: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-3204.
42. Sanossian N, Saver JL, Navab M, Ovbiagele B: High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke 2007;38:1104-1109.
43. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861.
44. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.
45. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P: Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003;163:669-676.
46. Costa J, Borges M, David C, Vaz Carneiro A: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials. BMJ 2006;332:1115-1124.
47. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
48. Heart Protection Study Collaborat ive Group; Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 pe ople with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645-654; discussion 653-654.
49. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
50. Wiviott SD, Cannon CP: The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 2006;17:626-630.
51. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, et al: Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70:2364-2370.
52. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al: Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39: 1647-1652.
53. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
54. Aslanyan S, Weir CJ, McInnes GT, Reid JL, Walters MR, Lees KR: Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol 2005;12:493-498.
55. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, et al: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117-1121.
56. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M: HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005;36:1298-1300.
57. Shook SJ, Gupta R, Vora NA, Tievsky AL, Katzan I, Krieger DW: Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. J Neuroimaging 2006;16:341-346.
58. Goldstein LB, Amarenco P, Callahan A, et al; on behalf of the SPARCL Investigators: The SPARCL trial: effect of statins on stroke severity (abstract T60); in 131st Annu Meet Am Neurol Assoc, October 2006, Chicago.
59. Alvarez-Sabin J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, et al: Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 2007;38:1076-1078.
60. Martínez-Sánchez P, Rivera-Ordóñez C, Fuentes B, Ortega Casarrubios MA, Aguilar MJ, Abenza MJ, et al: Treatment with statins is a factor of better outcome after an ischemic stroke, especially in the lacunar subtype. Stroke 2007;38:478.
61. Martínez-Sánchez P, Rivera-Ordóñez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, Díez-Tejedor E: The beneficial effect of statins treatment by stroke subtype. Eur J Neurol, in press.
62. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-1719.
63. Calabro P, Yeh ET: The pleiotropic effects of statins. Curr Opin Cardiol 2005;20:541-546.
64. Amarenco P, Moskowitz MA: The dynamics of statins: from event prevention to neuro-protect ion. Stroke 2006;37:294-296.
65. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, et al: Statin enhancement of collateralization in acute stroke. Neurology 2007;68:2129-2131.
66. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, et al: Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69:904-910.
67. Colivicchi F, Bassi A, Santini M, Caltagirone C: Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-2657.
68. Endres M, Laufs U: Discontinuation of statin treatment in stroke patients. Stroke 2006;37:2640-2643.
69. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, et al: Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003;34:551-557.
70. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718.
71. Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, Molina CA, et al: Simvastatin in the acute phase of ischemic stroke: a safety and eff icac y pilot trial. Eur J Neurol 2008;15:82-90.
72. Prinz V, Laufs U, Gertz K, Kronenberg G, Balkaya M, Leithner C, et al: Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008;39:433-438.